Literature DB >> 25811288

Analyses Comparing Visual Acuity Between Ranibizumab and Bevacizumab in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Gui-shuang Ying1, Maureen G Maguire1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25811288      PMCID： PMC4770887          DOI： 10.1001/jamaophthalmol.2015.0502

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  3 in total

1.  Comparative effectiveness of bevacizumab and ranibizumab in the comparison of age-related macular degeneration treatments trials.

Authors:  Andrea Messori
Journal:  JAMA Ophthalmol       Date:  2015-03       Impact factor: 7.389

2.  Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Authors:  Daniel F Martin; Maureen G Maguire; Stuart L Fine; Gui-shuang Ying; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Maryann Redford; Frederick L Ferris
Journal:  Ophthalmology       Date:  2012-05-01       Impact factor: 12.079

3.  Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.

Authors:  Gui-shuang Ying; Benjamin J Kim; Maureen G Maguire; Jiayan Huang; Ebenezer Daniel; Glenn J Jaffe; Juan E Grunwald; Kevin J Blinder; Christina J Flaxel; Firas Rahhal; Carl Regillo; Daniel F Martin
Journal:  JAMA Ophthalmol       Date:  2014-08       Impact factor: 7.389
  3 in total
  1 in total

1.  Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment.

Authors:  Ana I Oca; Álvaro Pérez-Sala; Ana Pariente; Rodrigo Ochoa; Sara Velilla; Rafael Peláez; Ignacio M Larráyoz
Journal:  J Pers Med       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.